Building a new model of sustainable chemistry. Meeting with Investors at VFB-Happening 2014 Karim Hajjar CFO

Similar documents
Solvay expands its specialty polymers offerings with Ryton PPS acquisition

Table of Contents. 1. About Solvay Solvay at a Glance Group Portfolio Transforming Solvay Solvay s Portfolio Upgrade 7

Solvay India April 2017

Launch of a new binders : Leveraging innovation to an economic advantage.

Building a model of sustainable chemistry

Nutrition Chris Goppelsroeder President & CEO DSM Nutritional Products ROYAL DSM HEALTH NUTRITION MATERIALS

Spiros Nomikos Chief Executive Officer Solvay Sodi Bulgaria

Nomura Healthcare Conference

CPH Chemie + Papier Holding AG. Investor Day. Perlen, 13 th September 2018

Value creation through profitable growth Handelsbanken Nordic Large Cap Seminar, Stockholm 2016 Anders Lonning-Skovgaard, CFO

For personal use only

ADM to Acquire Neovia and Probiotics International Limited. July 2, 2018

DIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM

GBU data & processes

BALCHEM CORPORATION. Q Investor Relations Presentation

Driving Profitable Growth

Consolidated: Financial Summary

ASKING MORE 2015 COMPLEMENTARY ANNUAL REPORT - SUSTAINABLE DEVELOPMENT INFORMATIONS

1Q2005. Hera Group presentation

January 30, 2018 Dow Wilson President and Chief Executive Officer

WELCOME TO ACTELION S AGM 2015

Solvay in India January, 2014

Value creation through profitable growth Danske Bank Winter Seminar 2017, Copenhagen Lars Rasmussen, President & CEO

Key figures (consolidated)

Forward Looking Information

1Q Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes

Opening New Frontiers

Third-quarter results 2013

KAPITALMARKNADSDAG 20 SEPTEMBER Thomas Axelsson, CEO

Welcome to the Full -Year Results Press Conference

For personal use only

Coloplast A/S. Investor presentation 1H 2005/06

MINUTES OF THE ANNUAL SOLVAY S.A. SHAREHOLDERS MEETING On Tuesday, May 10, 2016 at 10:30 a.m.

BANK HANDLOWY W WARSZAWIE S.A. 1Q 2009 consolidated financial results -1-

Südzucker Group Capital market forum Rhine Neckar

Human Nutrition Jeremy Xu President Human Nutritional & Health ROYAL DSM HEALTH NUTRITION MATERIALS

JP Morgan 2011 Healthcare Conference. David Redfern, Chief Strategy Officer 12 January 2011

FY2009 First Quarter Financial Results. SUZUKI MOTOR CORPORATION August 3, 2009

The acquisition of Fortitech

Consumer Wellness in India Growth Ahead

ST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015

Vision. Mission. Hopelink s Values. Introduction. A community free of poverty

A GLOBAL LEADER IN PERSONALIZED NUTRITION

ELICA 2012 Q3 RESULTS. November 14,

Summary of Results for the First Half of FY2015/3

Forward-Looking Statements

A world leader in allergy immunotherapy

ASX Investor Presentation

ResMed Inc. 36 th Annual J.P. Morgan Healthcare Conference

Walgreen Co. Reports Second Quarter 2010 Earnings Per Diluted Share of 68 Cents; Results Include 2 Cents Per Diluted Share of Restructuring Costs

Leading Intimate Healthcare. Investor presentation Q1 2007/08

Financial Presentation

Letter to Shareholders SEMI-ANNUAL REPORT 2008

Leading Intimate Healthcare

Enel Américas 1Q 2018 results

2014 Full Year Results Presentation. Year ended 31 March 2014

Results Presentation 2Q FY March Win-Partners Co., Ltd. (3183)

Passion for progress, care for people

Cowen Healthcare Conference

Very good Q3 contribution from Vegetable Juices Inc.

FIRSTQUARTER2018 RESULTSPRESENTATION

Results Presentation 2Q FY March Win-Partners Co., Ltd. (3183)

Waste Heat Recovery Opportunities in Cement Market and Supplier Analysis. Intercem Conference. Nairobi, Kenya June 16-18, 2014

Welcome to LG Electronics

Investor Day LA&C Region Lausanne, September 29, Jeanne Pollès President, Latin America & Canada Region

Q Investor Kit January December 2014

MANAGEMENT. MGMT 0021 THE MANAGEMENT PROCESS 3 cr. MGMT 0022 FINANCIAL ACCOUNTING 3 cr. MGMT 0023 MANAGERIAL ACCOUNTING 3 cr.

DuPont Nutrition & Health Craig Binetti, President

Q Investor Kit JANUARY-JUNE 2014

Q Investor Kit JANUARY-MARCH 2014

To be the partner of choice Straumann

UCB, with a strong year 2017, is reinforcing a solid foundation for investing in future growth

Investor Presentation. Q April 26, 2018

Dynamic Growth. Investora Gerhard Mahrle CFO COLTENE Holding AG. September 2018

Distribution Partner Briefing: A Partnership for Profit. Welcome to Smartcool s information package for prospective channel partners.

Imperial Brands Maximising Category Opportunities CAGNY February 2019

View Report Details. Global Coronary Stent Market

Global Invisible Braces Market: Trends, Opportunities and Forecasts ( )

Full Year Update FY2011 May 2011

Merrill Lynch Healthcare Conference New York

Merrill Lynch Conference Julian Heslop, CFO Sept 17 th 2010

Investor Presentation

Q Investor Kit JANUARY-JUNE 2013

Corporate Presentation October New growth cycle and value innovation

For personal use only

Uroplasty, Inc. Investor Update Canaccord Genuity Conference December 6, 2011

DELICA D:5 ACTIVE GEAR 0

A short introduction to DSM (2017) The global science-based company active in health, nutrition and materials

GN Store Nord Goldman Sachs European Medtech and Healthcare Services Conference. CEO GN ReSound, Mike van der Wallen September 3, 2008

FIRST QUARTER 2018 RESULTS 15 MAY 2018 LUCA BETTONTE, CEO

The Dental Corporation Opportunity

Slide 1. Financial update and closing remarks. Jesper Brandgaard EVP and CFO. RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A

GROWTH NOW! Franck Riboud

DSM Capital Markets Day 2018

Increase in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) H revenues and results - 24 July 2014

An exciting combination in a high growth, high margin Nutrition category. Name of chairman

Harm de Wildt MD TNI

William Demant. Jefferies Healthcare Conf. Nov Søren B. Andersson, VP Investor Relations

For personal use only

Immunity for Life TM. Third Quarter CEO Lars Viksmoen CFO Finn Samuelsen. 31 October 2007

Transcription:

Building a new model of sustainable chemistry Meeting with Investors at VFB-Happening 2014 Karim Hajjar CFO

Solvay at a glance Acceleration of Solvay s transformation Delivery in a challenging economic context Strong fundamentals to create value 2 Forenote All references to 2012 Income Statement data are restated for: the Group s new business organization effective as from January 1, 2013; the application of IAS 19 revised; the Group s European Chlorovinyls activities planned to be contributed to the JV with Ineos. The European Chlorovinyls business activities are reflected as Assets Held For Sale on the balance sheet (in one single line) and as discontinued operations in the Income Statement as required by IFRS. As from December 31, 2013, Benvic (the PVC compounding business) is reflected in the Balance Sheet as "Assets Held for Sale", but as continued operations in the Income Statement. Chemlogics is consolidated in the financial statements from November 1, 2013. Solvay is presenting Adjusted Income Statement performance indicators that exclude non-cash Purchase Price Allocation (PPA) accounting impacts related to the Rhodia acquisition. Furthermore, all figures are historical figures before restatement for IFRS 11 applied by Solvay as from Jan 1st 2014.

Solvay at a glance Acceleration of Solvay s transformation Delivery in a challenging economic context Strong fundamentals to create value 3

Solvay, a major global chemical player 9.9 bn Net sales 1.7 bn REBITDA Based on strengths Well-balanced geographical spread and end-user markets 117 Industrial sites 15 Major R&I centers 16.7% REBITDA margin Leading player in 90% of our businesses 29,400 Employees (EFTEs) 378 m Adjusted Net Income, Group share Strong R&I portfolio 56 Country presence All figures excluding discontinued operations, except for employees Building a new model of sustainable chemistry 4

Well-balanced geographical spread and end-user markets Balanced geographic exposure* Exposure to high growth end-markets* 5 North America 25% Latin America 11% Europe 33% * Figures represent % of 2013 net sales (pro-forma Chemlogics) Asia Pacific & RoW 31% Aeronautics & Automotive 17% Consumer Goods & Healthcare 25% Agro Food 12% Energy & Environment 11% Building & Construction 10% Electrical & Electronics 6% Industrial Applications 19%

Building a new model of sustainable chemistry Our commitments Planet Customers Reach excellence in safety & health Deploy unmatched sustainable portfolio management Reduce our impact on environment by 2020 Investors Suppliers Energy consumption Greenhouse gas emissions Groundwater consumption Air emission Water emissions Sustainable water management Communities Develop rich & balanced social dialogue Employees 6

Solvay at a glance Acceleration of Solvay s transformation Delivery in a challenging economic context Strong fundamentals to create value 7

Converting vision into value Our vision Our 2016 ambition Build a strong global leader in the chemical industry Be a model of sustainable chemistry Become a high growth, less capital intensive & high return Group REBITDA to reach 2.3-2.5 bn REBITDA margin to reach 18% CFROI* to increase by >100 bp vs 2013 2/3 rd of businesses in value-creation zone Being a model of sustainability Reducing our impact on environment * CFROI = REBITDA Rec. Capex Tax Gross assets + Working Capital 8

A clearly defined strategy Our strategy Business profile enhanced Reinforcing business profile through strategic portfolio changes Striving for excellence across businesses Innovating to create sustainable solutions Solvay s ability to extract value ENHANCE Solvay YE 2012 RESTORE GROW Solvay YE 2013 Chemlogics Chemical industry Transforming company culture with a focus on performance EXIT Value creation potential of industry segment Solvay businesses 9

Strong innovation portfolio aligned with global megatrends 2013 Climate change 15 Resource scarcity Advanced materials Major sites worldwide 1,950 Advanced formulations R&I staff Health & well being Renewable chemistry R&I efforts 22% Next bn consumers Organic electronics Q4 & FY 2013 results 26/02/2014 New sales ratio Sustainable energy Ecoprocesses 10 280 m 251 Patents filed

REBITDA growth supported by strong operational levers REBITDA In m Inflation Operational excellence > 10% CAGR Organic growth Innovation Portfolio 2,300-2,500 250 1,663 Chemlogics (10 months) (260) 300 Industrial excellence Purchasing, supply & other efficiencies 280 New production capacities Commercial excellence Innovative products Innovation excellence Example: 2013* 2016 * Chemlogics consolidated for 2 months 11

A strong team with a proven track record Executive Committee as of Jan 1st, 2014 Jean-Pierre Clamadieu Karim Hajjar Vincent De Cuyper Pascal Juery Roger Kearns Jacques van Rijckevorsel CEO CFO Advanced Formulations Advanced Materials Performance Chemicals Functional Polymers Solvay Energy Services E. Butstraen Novecare A. Di Donfrancesco Specialty Polymers C. Clemente Soda Ash M. Laudenbach Polyamide & Intermediates P. Rosier Solvay Energy Services V. Kamel Coatis T. Benner Silica G. Crauser Peroxides F. Hincker Engineering Plastics D. Rage Aroma Performance H. Du Rare Earth Systems O. Ferrary Acetow F. Ferraroli Fibras B. Wilkes J. Harton Special Chemicals Eco Services B. Van der Wielen Emerging Biochemicals 12

A performance culture to move from good to great Internal campaign Customer-centric, empowered, entrepreneurial, result-oriented Employer branding campaign 13

Solvay at a glance Acceleration of Solvay s transformation Delivery in a challenging economic context Strong fundamentals to create value 14

FY 2013 results: demonstrating our resilience in a difficult environment Net Sales 9.9 bn (5)% yoy Forex headwinds Raw materials deflation Volume decrease primarily related to CER phase-out REBITDA 1,663 m (12)% yoy Stable allowing for exceptionals & Chemlogics CER phase-out and guar effect exceptionals Pricing power preserved Excellence programs delivering Net Income 378 m Adjusted, Group Share Significant non-recurring costs (239) m (e.g. restructuring for integration and excellence) FCF 524 m Net Debt 1,102 M Strong Free Cash Flow Stable Net Debt Hybrid bonds of 1.2 bn classified in Equity Stable dividend proposed at 3.20 gross / share 15

Stable underlying REBITDA allowing for exceptionals (carbon credits and guar) In m 1,896 17-126 Pricing power +3 M 1 % Structure Carbon credits -7 % Volumes & mix -202 205-36 Guar -11 % Selling price 11 % Raw materials & energy costs -2 % Fixed costs ~-100 Guar -5% Result of Hichem JV 9 1% Others Other JV results ~ 18 Conversion -36 Other 27 1,663-12 % 2012 2013 Margin Margin 18.0% 16.7% 16

Stable total dividend proposed Solvay s gross dividend in /share 2013 CAGR >5% 3.20 / share (gross) dividend proposed 1.33 interim dividend paid in January 2014 1.87 balance to be paid in May 2014 1982 1987 1992 1997 2002 2007 2012 Over more than 30 years 40% average pay out Committed to stable / growing dividend 17

Solvay share price performance compared to indexes since January 2012 Until April 22, 2014 195 175 Solvay +77% 155 135 BEL 20 CAC 40 115 95 75 January 2012 January 2013 April 2014 18

Solvay at a glance Acceleration of Solvay s transformation Delivery in a challenging economic context Strong fundamentals to create value 19

Executing a clear value creation strategy Progress on many fronts Poised for growth On track towards 2016 targets Towards a higher growth, improved cash generation & enhanced returns Chemical Group Targeting Sustainable Value Growth 20